Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Loss of Nmp4 optimizes osteogenic metabolism and secretion to enhance bone quality.

Shao Y, Wichern E, Childress PJ, Adaway M, Misra J, Klunk A, Burr DB, Wek RC, Mosley AL, Liu Y, Robling AG, Brustovetsky N, Hamilton J, Jacobs K, Vashishth D, Stayrook KR, Allen MR, Wallace JM, Bidwell JP.

Am J Physiol Endocrinol Metab. 2019 May 1;316(5):E749-E772. doi: 10.1152/ajpendo.00343.2018. Epub 2019 Jan 15.

PMID:
30645175
2.

HDX reveals the conformational dynamics of DNA sequence specific VDR co-activator interactions.

Zheng J, Chang MR, Stites RE, Wang Y, Bruning JB, Pascal BD, Novick SJ, Garcia-Ordonez RD, Stayrook KR, Chalmers MJ, Dodge JA, Griffin PR.

Nat Commun. 2017 Oct 13;8(1):923. doi: 10.1038/s41467-017-00978-7.

3.

Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow.

Clinkenbeard EL, Hanudel MR, Stayrook KR, Appaiah HN, Farrow EG, Cass TA, Summers LJ, Ip CS, Hum JM, Thomas JC, Ivan M, Richine BM, Chan RJ, Clemens TL, Schipani E, Sabbagh Y, Xu L, Srour EF, Alvarez MB, Kacena MA, Salusky IB, Ganz T, Nemeth E, White KE.

Haematologica. 2017 Nov;102(11):e427-e430. doi: 10.3324/haematol.2017.167882. Epub 2017 Aug 17. No abstract available.

4.

Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.

Shao Y, Hernandez-Buquer S, Childress P, Stayrook KR, Alvarez MB, Davis H, Plotkin LI, He Y, Condon KW, Burr DB, Warden SJ, Robling AG, Yang FC, Wek RC, Allen MR, Bidwell JP.

Endocrinology. 2017 Sep 1;158(9):2722-2740. doi: 10.1210/en.2017-00355.

5.

Genome-Wide Mapping and Interrogation of the Nmp4 Antianabolic Bone Axis.

Childress P, Stayrook KR, Alvarez MB, Wang Z, Shao Y, Hernandez-Buquer S, Mack JK, Grese ZR, He Y, Horan D, Pavalko FM, Warden SJ, Robling AG, Yang FC, Allen MR, Krishnan V, Liu Y, Bidwell JP.

Mol Endocrinol. 2015 Sep;29(9):1269-85. doi: 10.1210/me.2014-1406. Epub 2015 Aug 5.

6.

TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.

Stayrook KR, Mack JK, Cerabona D, Edwards DF, Bui HH, Niewolna M, Fournier PG, Mohammad KS, Waning DL, Guise TA.

Bonekey Rep. 2015 Jul 8;4:719. doi: 10.1038/bonekey.2015.88. eCollection 2015.

7.

HDX reveals unique fragment ligands for the vitamin D receptor.

Carson MW, Zhang J, Chalmers MJ, Bocchinfuso WP, Holifield KD, Masquelin T, Stites RE, Stayrook KR, Griffin PR, Dodge JA.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3459-63. doi: 10.1016/j.bmcl.2014.05.070. Epub 2014 May 29.

PMID:
24974344
8.

Role of TGF-β in breast cancer bone metastases.

Chiechi A, Waning DL, Stayrook KR, Buijs JT, Guise TA, Mohammad KS.

Adv Biosci Biotechnol. 2013 Oct 1;4(10C):15-30.

9.

The role of TGF-β in bone metastasis: novel therapeutic perspectives.

Buijs JT, Stayrook KR, Guise TA.

Bonekey Rep. 2012 Jun 6;1:96. doi: 10.1038/bonekey.2012.96. eCollection 2012.

10.

Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.

Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE.

Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):E1146-55. doi: 10.1073/pnas.1110905108. Epub 2011 Oct 17.

11.

TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases.

Buijs JT, Stayrook KR, Guise TA.

Cancer Microenviron. 2011 Dec;4(3):261-81. doi: 10.1007/s12307-011-0075-6. Epub 2011 Jul 12.

12.

DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex.

Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Wang Y, Busby SA, Pascal BD, Garcia-Ordonez RD, Bruning JB, Istrate MA, Kojetin DJ, Dodge JA, Burris TP, Griffin PR.

Nat Struct Mol Biol. 2011 May;18(5):556-63. doi: 10.1038/nsmb.2046. Epub 2011 Apr 10.

13.

Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer.

Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Garcia-Ordonez RD, Pascal BD, Burris TP, Dodge JA, Griffin PR.

Structure. 2010 Oct 13;18(10):1332-41. doi: 10.1016/j.str.2010.07.007.

14.

Regulation of adipogenesis by natural and synthetic REV-ERB ligands.

Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, Kamenecka TM, Stayrook KR, Crumbley C, Floyd ZE, Gimble JM, Griffin PR, Burris TP.

Endocrinology. 2010 Jul;151(7):3015-25. doi: 10.1210/en.2009-0800. Epub 2010 Apr 28.

15.

A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia.

Sato M, Lu J, Iturria S, Stayrook KR, Burris LL, Zeng QQ, Schmidt A, Barr RJ, Montrose-Rafizadeh C, Bryant HU, Ma YL.

J Bone Miner Res. 2010 Jun;25(6):1326-36. doi: 10.1002/jbmr.15.

16.

Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands.

Wang Y, Kumar N, Solt LA, Richardson TI, Helvering LM, Crumbley C, Garcia-Ordonez RD, Stayrook KR, Zhang X, Novick S, Chalmers MJ, Griffin PR, Burris TP.

J Biol Chem. 2010 Feb 12;285(7):5013-25. doi: 10.1074/jbc.M109.080614. Epub 2009 Dec 4.

17.

The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene.

Wang Y, Rogers PM, Stayrook KR, Su C, Varga G, Shen Q, Nagpal S, Burris TP.

Mol Pharmacol. 2008 Dec;74(6):1716-21. doi: 10.1124/mol.108.048538. Epub 2008 Sep 24.

PMID:
18815215
18.

Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha.

Wang Y, Rogers PM, Su C, Varga G, Stayrook KR, Burris TP.

J Biol Chem. 2008 Sep 26;283(39):26332-9. doi: 10.1074/jbc.M804808200. Epub 2008 Aug 1.

19.

Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta.

Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, Burris LL, Khorasanizadeh S, Burris TP, Rastinejad F.

Nat Struct Mol Biol. 2007 Dec;14(12):1207-13. Epub 2007 Nov 25.

20.

Regulation of human 3 alpha-hydroxysteroid dehydrogenase (AKR1C4) expression by the liver X receptor alpha.

Stayrook KR, Rogers PM, Savkur RS, Wang Y, Su C, Varga G, Bu X, Wei T, Nagpal S, Liu XS, Burris TP.

Mol Pharmacol. 2008 Feb;73(2):607-12. Epub 2007 Nov 16.

PMID:
18024509
21.

Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators.

Ma Y, Khalifa B, Yee YK, Lu J, Memezawa A, Savkur RS, Yamamoto Y, Chintalacharuvu SR, Yamaoka K, Stayrook KR, Bramlett KS, Zeng QQ, Chandrasekhar S, Yu XP, Linebarger JH, Iturria SJ, Burris TP, Kato S, Chin WW, Nagpal S.

J Clin Invest. 2006 Apr;116(4):892-904. Epub 2006 Mar 9.

22.

Coactivation of the human vitamin D receptor by the peroxisome proliferator-activated receptor gamma coactivator-1 alpha.

Savkur RS, Bramlett KS, Stayrook KR, Nagpal S, Burris TP.

Mol Pharmacol. 2005 Aug;68(2):511-7. Epub 2005 May 20.

PMID:
15908514
23.

The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand.

Burris TP, Montrose C, Houck KA, Osborne HE, Bocchinfuso WP, Yaden BC, Cheng CC, Zink RW, Barr RJ, Hepler CD, Krishnan V, Bullock HA, Burris LL, Galvin RJ, Bramlett K, Stayrook KR.

Mol Pharmacol. 2005 Mar;67(3):948-54. Epub 2004 Dec 15.

PMID:
15602004
24.

Regulation of carbohydrate metabolism by the farnesoid X receptor.

Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP.

Endocrinology. 2005 Mar;146(3):984-91. Epub 2004 Nov 24.

PMID:
15564327
25.

Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation.

Bettoun DJ, Burris TP, Houck KA, Buck DW 2nd, Stayrook KR, Khalifa B, Lu J, Chin WW, Nagpal S.

Mol Endocrinol. 2003 Nov;17(11):2320-8. Epub 2003 Jul 31.

PMID:
12893883
26.

Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis.

Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, Zhang Y, Stayrook KR, Suen C, Otto KA, Miller AR, Dai J, Foxworthy P, Gao H, Ryan TP, Jiang XC, Burris TP, Eacho PI, Etgen GJ.

J Biol Chem. 2003 Jan 10;278(2):1131-6. Epub 2002 Oct 31.

27.

Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells.

Stayrook KR, McKinzie JH, Barbhaiya LH, Crowell PL.

Anticancer Res. 1998 Mar-Apr;18(2A):823-8.

PMID:
9615726
28.
29.

Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases.

Cates CA, Michael RL, Stayrook KR, Harvey KA, Burke YD, Randall SK, Crowell PL, Crowell DN.

Cancer Lett. 1996 Dec 20;110(1-2):49-55.

PMID:
9018080

Supplemental Content

Loading ...
Support Center